Efficacy of baricitinib 4 mg in patients with moderate‐to‐severe atopic dermatitis previously treated with systemic therapy
Abstract Background The Janus kinase (JAK)1/JAK2 inhibitor baricitinib in combination with topical corticosteroids (TCS) improved moderate‐to‐severe atopic dermatitis (AD) in the phase 3 BREEZE‐AD7 trial. Patients with previous systemic therapy may have more severe, treatment‐resistant disease. Obje...
Saved in:
Main Authors: | , , , , , , , , , |
---|---|
Format: | Book |
Published: |
Wiley,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Internet
Connect to this object online.3rd Floor Main Library
Call Number: |
A1234.567 |
---|---|
Copy 1 | Available |